During the last session, ImmunityBio Inc (NASDAQ:IBRX)’s traded shares were 2.28 million, with the beta value of the company hitting 0.91. At the end of the trading day, the stock’s price was $3.95, reflecting an intraday gain of 3.95% or $0.15. The 52-week high for the IBRX share is $10.53, that puts it down -166.58 from that peak though still a striking 68.35% gain since the share price plummeted to a 52-week low of $1.25. The company’s market capitalization is $2.75B, and the average intraday trading volume over the past 10 days was 2.66 million shares, and the average trade volume was 3.16 million shares over the past three months.
ImmunityBio Inc (IBRX) received a consensus recommendation of Sell from analysts. That translates to a mean rating of 2.00. IBRX has a Sell rating from 1 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunityBio Inc (NASDAQ:IBRX) trade information
ImmunityBio Inc (IBRX) registered a 3.95% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.95% in intraday trading to $3.95, hitting a weekly high. The stock’s 5-day price performance is -7.06%, and it has moved by -17.54% in 30 days. Based on these gigs, the overall price performance for the year is 139.39%. The short interest in ImmunityBio Inc (NASDAQ:IBRX) is 49.18 million shares and it means that shorts have 15.93 day(s) to cover.
The consensus price target of analysts on Wall Street is $8, which implies an increase of 50.62% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8 and $8 respectively. As a result, IBRX is trading at a discount of -102.53% off the target high and -102.53% off the low.
ImmunityBio Inc (IBRX) estimates and forecasts
Statistics show that ImmunityBio Inc has underperformed its competitors in share price, compared to the industry in which it operates. ImmunityBio Inc (IBRX) shares have gone down -16.14% during the last six months, with a year-to-date growth rate less than the industry average at 13.13% against 18.00.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.17%. While earnings are projected to return 25.22% in 2024, the next five years will return -1.70% per annum.
IBRX Dividends
ImmunityBio Inc is due to release its next quarterly earnings on 2024-Nov-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
ImmunityBio Inc insiders own 77.04% of total outstanding shares while institutional holders control 9.15%, with the float percentage being 39.83%. VANGUARD GROUP INC is the largest shareholder of the company, while 258.0 institutions own stock in it. As of 2024-06-30, the company held over 13.83 million shares (or 2.0558% of all shares), a total value of $87.42 million in shares.
The next largest institutional holding, with 11.42 million shares, is of BLACKROCK INC.’s that is approximately 1.6978% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $72.19 million.
Also, the Mutual Funds coming in first place with the largest holdings of ImmunityBio Inc (IBRX) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund . Data provided on Jul 31, 2024 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 4.64 shares. This amounts to just over 0.67 percent of the company’s overall shares, with a $18.34 million market value. The same data shows that the other fund manager holds slightly less at 4.2, or about 0.60% of the stock, which is worth about $16.59 million.
